About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Zydus Lifesciences Ltd.
Change Company
BSE Code
532321
ISIN Demat
INE010B01027
Book Value
210.59
NSE Code
ZYDUSLIFE
Dividend Yield %
1.15
Market Cap
964123.10
P/E
16.70
EPS
57.39
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
04-Jun-2025
Zydus Lifesciences’ arm enters into SPA with Agen...
04-Jun-2025
Zydus Lifesciences trades marginally higher as it...
02-Jun-2025
Zydus Lifesciences gets USFDA’s tentative approva...
02-Jun-2025
Zydus Lifesciences informs about press release
29-May-2025
Zydus Lifesciences to subscribe equity shares of ...
29-May-2025
Zydus Lifesciences gains on entering to SSSA to s...
28-May-2025
Zydus Lifesciences’ NCE Usnoflast receives Fast T...
28-May-2025
Zydus Lifesciences informs about press release
28-May-2025
Zydus Lifesciences rises as its NCE Usnoflast rec...
26-May-2025
Zydus Lifesciences gets USFDA’s final nod for Iso...
26-May-2025
Zydus Lifesciences gains on getting USFDA’s final...
14-May-2025
Zydus Lifesciences receives EIR from USFDA for Am...
09-May-2025
Zydus Lifesciences gets USFDA’s approval for Glat...
09-May-2025
Zydus Lifesciences rises on getting USFDA’s appro...
30-Apr-2025
Zydus Lifesciences gets USFDA’s final approval fo...
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.